These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 8137645)
1. [Relation between DNA content in ovarian cystadenoma and its pathohistology]. Sun ZC Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645 [TBL] [Abstract][Full Text] [Related]
2. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma]. Liu C; Zhao Y; Sun X Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma]. Lu XL; Yi WM; Wang LF Ai Zheng; 2003 Jan; 22(1):62-5. PubMed ID: 12561439 [TBL] [Abstract][Full Text] [Related]
4. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary. Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547 [TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D; Hirschmann A; Löhrs U; Diebold J Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438 [TBL] [Abstract][Full Text] [Related]
6. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection. Zhou F; Cao X; Liu M; Wang Y; Tao G Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835 [TBL] [Abstract][Full Text] [Related]
7. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy]. Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214 [TBL] [Abstract][Full Text] [Related]
8. Association of decreased mitochondrial DNA content with ovarian cancer progression. Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344 [TBL] [Abstract][Full Text] [Related]
10. [Accuracy of frozen section in diagnosis of ovarian tumors]. Zhang GN Zhonghua Fu Chan Ke Za Zhi; 1993 Oct; 28(10):601-3, 635. PubMed ID: 8112130 [TBL] [Abstract][Full Text] [Related]
11. [Tumor necrosis factor gene expression in ovarian tumor]. Gao SF; Zhang SZ; Zhang MH Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):389-91, 443. PubMed ID: 8001412 [TBL] [Abstract][Full Text] [Related]
12. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138 [TBL] [Abstract][Full Text] [Related]
13. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors. Li XS; Sun J; He XL Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304 [TBL] [Abstract][Full Text] [Related]
14. DNA flow cytometric evaluation of serous and mucinous cystic neoplasms of the pancreas. Unger PD; Danque PO; Fuchs A; Kaneko M Arch Pathol Lab Med; 1991 Jun; 115(6):563-5. PubMed ID: 2039342 [TBL] [Abstract][Full Text] [Related]
15. [Mural nodules of anaplastic carcinoma in bilateral ovarian borderline mucinous cystadenoma: a case report]. Guilbeau C; Soubeyrand MS; Devillebichot C; Sage M; Collin F; Arnould L Ann Pathol; 2003 Sep; 23(4):340-4. PubMed ID: 14597898 [TBL] [Abstract][Full Text] [Related]
16. [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms]. Xie D; Yang GF; Chen YQ; Jiang LF; Xiao LZ Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):911-4. PubMed ID: 17533742 [TBL] [Abstract][Full Text] [Related]
17. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981 [TBL] [Abstract][Full Text] [Related]
18. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances]. Hu YQ; Liu YJ Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259 [TBL] [Abstract][Full Text] [Related]
20. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. Zhong M; Li J; Ding YQ; Song LL Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]